BioCentury | May 1, 2020
Finance

As market’s upbeat April draws to close, Lyra becomes latest biotech IPO to surge

Lyra became the latest biotech to gain value after pricing its IPO at the top of its range, signaling continued strength among the sector’s new listings in a season of volatility. The ear, nose and...
BioCentury | May 30, 2019
Clinical News

May 30 Clinical Quick Takes: Cancer report shows decline in mortality from melanoma; plus Cara, Novartis

Decrease in mortality from melanoma attributed to checkpoint inhibitors The rate of death due to melanoma of the skin declined by 8.5% per year during 2014-16 among men and 6.3% per year in 2013-16 among...
BioCentury | Mar 1, 2019
Clinical News

Phase III nasal polyps data for Dupixent presented at AAAAI

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and partner Sanofi (Euronext:SAN; NYSE:SNY) presented detailed data at the American Academy of Allergy, Asthma & Immunology meeting from a pair of Phase III trials evaluating Dupixent dupilumab to treat recurring...
BioCentury | Sep 28, 2018
Financial News

Perceptive leads Lyra's $29.5M series B

Ears, nose and throat disease company Lyra Therapeutics Inc. (Watertown, Mass.) raised $29.5 million in a series B round led by Perceptive Advisors. Fellow new investors RA Capital, ArrowMark Partners and Soleus Capital also participated,...
BioCentury | Sep 26, 2018
Financial News

Perceptive leads Lyra’s $29.5M series B

Ears, nose and throat disease company Lyra Therapeutics Inc. (Watertown, Mass.) raised $29.5 million in a series B round led by Perceptive Advisors. Fellow new investors RA Capital, ArrowMark Partners and Soleus Capital also participated,...
BioCentury | Aug 17, 2018
Company News

Perrigo to separate its generics business

Perrigo Co. plc (NYSE:PRGO; Tel Aviv:PRGO) said it plans to separate its prescription generics business to focus on its consumer healthcare products. The company expects the transaction -- which could include a separation to shareholders,...
BioCentury | Mar 16, 2018
Clinical News

Glenmark's Ryaltris meets in Phase III for seasonal allergic rhinitis

Glenmark Pharmaceuticals Ltd. (NSE:GLENMARK; BSE:532296) reported data from a Phase III trial in 1,180 patients with seasonal allergic rhinitis showing that twice-daily Ryaltris mometasone/olopatadine met the primary endpoint of improving average morning and evening patient-reported...
BioCentury | Dec 22, 2017
Clinical News

Glenmark's Ryaltris meets in Phase III for perennial allergic rhinitis

Glenmark Pharmaceuticals Ltd. (NSE:GLENMARK; BSE:532296) reported top-line data showing that twice-daily Ryaltris mometasone/olopatadine (formerly GSP 301) met the primary safety endpoint and a secondary efficacy endpoint in a Phase III trial to treat perennial allergic...
BioCentury | Jan 11, 2016
Clinical News

Indacaterol/glycopyrronium bromide/mometasone fuorate: Phase III started

Vectura and Sosei said Novartis began a double-blind, international Phase III trial to compare 2 dose levels of inhaled QVM149 vs. 2 dose levels of Novartis’ inhaled indacaterol/mometasone furoate ( QMF149 ) or salmeterol xinafoate /fluticasone propionate...
BioCentury | Oct 6, 2014
Clinical News

Dupilumab: Phase IIa data

Top-line data from a double-blind, international Phase IIa trial in 60 patients with moderate to severe chronic sinusitis with nasal polyps who did not respond to intranasal corticosteroids showed that once-weekly subcutaneous dupilumab met the...
Items per page:
1 - 10 of 46